Collaborative Center for Translational Mass Spectrometry

What if doctors had a way to detect disease in its earliest stages? What if they could monitor the effectiveness of a particular therapy, or match with certainty the right patient with the right drug? The answers may lie in protein biomarkers.

Protein biomarkers - biological indicators of health or disease states – hold potential to advance these goals and truly revolutionize our understanding and treatment of disease in all its states.

Yet, a biomarker development gap exists, despite more than 40,000 publications purporting an association of biomarkers to specific diseases, and use in U.S. Food and Drug Administration (FDA) efforts to overhaul our healthcare system. Between 2003 and 2008, the FDA approved only eight new protein biomarkers.

TGen’s Collaborative Center for Translational Mass Spectrometry seeks to fill this biomarker development gap by amassing the critical expertise and instrumentation in a single, regulatory-compliant environment capable of executing across all phases of the biomarker development pipeline from discovery through clinical validation.

In addition to providing biomarker discovery capabilities to the TGen community, the Center houses a world-class, first-of-its kind proteomics biomarker verification unit. There, faculty incorporate high-throughput, robotically automated workflows that standardize biological sample preparation, limit sample-to-sample variability, and enhance downstream mass spectrometry-based analysis for large-scale verification studies. The state-of-the-art equipment in both the wet chemistry and mass spectrometry facilitate the simultaneous processing and analysis of hundreds of biomarkers across thousands of patient samples.

Contact
Patrick Pirrotte, Ph.D.
Technical Director & Research Assistant Professor
ppirrotte@tgen.org
P: 602-343-8454